Roche has received CE mark certification for the new and enhanced cobas 6800/8800 systems 2.0, boosting laboratory efficiency and testing capabilities.
This update is expected to optimise resources, reduce downtime, consolidate test menus, and allow sample prioritisation. It also increases throughput, offering healthcare professionals and patients a more streamlined diagnostic experience.
The cobas 6800/8800 systems are tailored for mid-to-high-volume molecular testing laboratories. They help in automating and integrating the workflow for polymerase chain reaction (PCR)- based nucleic acid testing (NAT).
According to Roche, the molecular laboratory instrument addresses common challenges with intelligent workflows, throughput, and reliability. The systems also offer flexibility and are designed to boost the testing experience.
The Swiss biotechnology company has updated the cobas 6800/8800 systems with the new Temperature-Activated Generation of Signal (TAGS) technology. This innovation enables the simultaneous detection of up to 15 targets in a single patient sample on the cobas 5800, 6800, and 8800 systems.
Laboratories can now perform a broader range of tests with a single solution, simplifying logistics and optimising resource use.
This update brings significant advancements to the cobas family, providing a unified user experience across all systems, including the latest addition, the cobas 5800, which was launched in late 2022.
The enhanced version of the cobas 6800/8800 systems is now available as an upgrade for existing systems in healthcare settings worldwide.
Roche Diagnostics CEO Matt Sause said: “This update marks another significant milestone for Roche.
“With our history of leading innovation in automated molecular testing, it represents another competitive leap forward in our efforts to advance PCR technology by combining unprecedented throughput together with the flexibility that laboratories require to deliver for physicians and patients.”
Roche is also awaiting 510(k) clearance from the US Food and Drug Administration (FDA), with submission planned for 2025.
Last month, the biotechnology company received a CE mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as a companion diagnostic. The assay is designed to identify ovarian cancer patients who may benefit from targeted therapy.
